Nkọwa
A na-eji nlezianya emepụta Omeprazole intermediate 2.3.5-Trimethyl-4-nitropyridine-N-oxide iji mezuo ụkpụrụ ụlọ ọrụ kachasị elu, na-eme ka ọ dị ọcha na ịdị irè ya ma nwee ike iji ya mee ihe n'ụdị kemịkalụ na usoro ọgwụ.Na ya kpọmkwem mejupụtara na ahụkebe àgwà, a compound bụ a zuru okè nhọrọ maka na-eme nnyocha, ndị ọkà mmụta sayensị na ọgwụ ọkachamara na-achọ a pụrụ ịdabere na, elu-arụmọrụ intermediates maka ha oru ngo.
Nke a na etiti na-ekere òkè dị mkpa n'imepụta omeprazole, ọgwụ a na-ejikarị agwọ ọrịa ndị metụtara acid dị ka ọrịa reflux gastroesophageal (GERD), ọnya peptic, na zolin (Guardian-Ellison syndrome).Dị ka akụkụ bụ isi na njikọ nke omeprazole, omeprazole nke etiti 2.3.5-trimethyl-4-nitropyridine-N-oxide na-akwado mmepụta nke ọma na ọnụ ahịa nke ọgwụ a dị mkpa.
Họrọ Anyị
JDK nwere ụlọ nrụpụta klaasị mbụ yana akụrụngwa njikwa ogo, nke na-emesi nnabata nke etiti API kwụsiri ike.Ndị otu ọkachamara na-emesi R&D obi ike maka ngwaahịa a.megide abụọ, anyị na-achọ CMO & CDMO n'ime ụlọ na mba ahịa.